Juul Labs Inc. v. Altria et al.

This patent infringement litigation involves Juul Labs Inc., an American electronic cigarette company known for its Juul vaping devices and nicotine salt formulations. The plaintiff, Juul Labs, initiated an investigation at the U.S. International Trade Commission (ITC) against Altria Group, Inc., a major U.S.-focused tobacco and nicotine company, and its NJOY unit. Altria acquired NJOY in 2023 as part of its strategy to transition adult smokers to smoke-free products, having previously held a significant stake in Juul Labs which it divested before acquiring NJOY. NJOY manufactures and sells e-vapor products, including the NJOY ACE and NJOY DAILY devices.

The accused products in this investigation (337-TA-1460) are "certain vaporizer devices, cartridges used therewith, and components thereof," specifically targeting NJOY's e-vapor products, including the NJOY DAILY. Juul Labs alleged that these imported NJOY products infringe U.S. Patent No. 12,156,533 ("the '533 patent"). This patent broadly covers nicotine salt liquid formulations for generating an inhalable aerosol in electronic cigarettes, where the formulation comprises a nicotine salt in a biologically acceptable liquid carrier, and an acid used to form the nicotine salt is characterized by a vapor pressure of about 20 to 200 mmHg at 200° C..

The procedural posture for this case was an investigation before the U.S. International Trade Commission (ITC), filed on September 12, 2025, and terminated on April 14, 2026. The ITC is a significant venue for patent infringement disputes, particularly for cases involving imported goods, because it can issue powerful remedies such as exclusion orders that bar infringing products from entering the U.S. market, and cease-and-desist orders. Unlike federal district courts, the ITC cannot award monetary damages but offers a faster resolution timeframe, often concluding within 15-18 months. The case is notable due to the ongoing competitive and legal battles between Juul and Altria/NJOY in the rapidly evolving e-vapor market, particularly after Altria's acquisition of NJOY following its exit from Juul. This investigation was one of several patent disputes between the two companies, highlighting the intense competition for market share in the electronic nicotine delivery systems (ENDS) industry. The final initial determination found all asserted claims of US Patent 12,156,533 invalid, leading to a finding of no violation.

Key Legal Developments and Outcome

This section details the key legal developments in Juul Labs Inc. v. Altria et al. (337-TA-1460), focusing on the chronological progression of the case within the U.S. International Trade Commission (ITC) and its final disposition.

Filing & Initial Pleadings

• Complaint Filed: Juul Labs Inc. filed its complaint with the U.S. International Trade Commission on August 8, 2025. The complaint alleged violations of Section 337 of the Tariff Act of 1930 due to the importation and sale of certain vaporizer devices, cartridges, and components thereof, specifically NJOY's e-vapor products, that allegedly infringed U.S. Patent No. 12,156,533 ("the '533 patent"). Juul sought a limited exclusion order and cease and desist orders.
• Investigation Instituted: The USITC voted to institute the investigation (337-TA-1460) on September 9, 2025. A formal notice of institution was published on September 12, 2025. The respondents identified were NJOY, LLC; NJOY Holdings, Inc.; Altria Group, Inc.; Altria Group Distribution Company; and Altria Client Services LLC.
• Answer: Respondents, including Altria Client Services LLC, filed their answer on November 20, 2025. An additional answer was filed on February 12, 2026, and February 18, 2026.

Pre-trial Motions of Substance

• Motions to Amend Procedural Schedule: On January 30, 2026, the parties filed a joint motion to amend the procedural schedule, particularly concerning deadlines for fact and expert discovery and summary determination motions. The Administrative Law Judge (ALJ) granted the motion in part, amending discovery deadlines and setting a summary determination motion deadline of March 20, 2026. However, NJOY's request to change the dates of the evidentiary hearing was denied, with the hearing remaining scheduled for April 22-24, 27, and 28, 2026.
• Partial Withdrawal of Complaint: On March 3, 2026, Juul filed an unopposed motion for partial termination of the investigation, withdrawing claims 7 and 8 of the '533 patent. The ALJ granted this motion, and on March 25, 2026, the Commission determined not to review the initial determination, thereby terminating claims 7 and 8 from the investigation. The initial complaint had alleged infringement of claims 1-8 and 10 of the '533 patent.
• Summary Determination of Invalidity: The final initial determination (ID) was issued by ALJ Doris Johnson Hines on April 13, 2026, and noticed on April 14, 2026. This ID granted NJOY's motion for summary determination of invalidity, concluding that each asserted claim of the '533 patent was invalid under 35 U.S.C. § 102(a)(1). Specifically, the ID found no violation of Section 337 because every asserted claim was invalid.

Claim Construction (Markman) Outcomes

• A Markman hearing was held on January 7, 2026. The outcome of this hearing regarding claim construction was a precursor to the summary determination on invalidity.

Discovery Milestones

• Fact discovery was initially set to close on January 21, 2026, but was extended through the January 30, 2026, order amending the procedural schedule. The order also extended deadlines for motions to compel, exchange of initial and rebuttal expert reports, and expert discovery.

Trial Events, Verdict, and Post-Trial Motions

• An evidentiary hearing was scheduled for April 22-24, 27, and 28, 2026. However, given the summary determination of invalidity issued on April 13, 2026, finding no violation, it is likely the evidentiary hearing did not proceed as originally planned for the asserted claims.

Settlement, Dismissal, Judgment, or Appeal

• Initial Determination of No Violation: As noted, the ALJ issued a final initial determination on April 13, 2026, finding no violation of Section 337. This determination was based on the finding that all asserted claims of U.S. Patent No. 12,156,533 were invalid under 35 U.S.C. § 102(a)(1).
• Termination of Investigation: The investigation was terminated on April 14, 2026, consistent with the initial determination of no violation.
• Appeal: The current status indicates "No Violation Found." The initial determination is subject to review by the full Commission.

Parallel PTAB IPR/PGR Proceedings

• IPR2026-00161: NJOY LLC filed an Inter Partes Review (IPR) petition against Juul Labs Inc. targeting U.S. Patent No. 12,156,533 (the '533 patent) on November 26, 2025. The last docket activity for this IPR was on March 31, 2026. While the ITC investigation found the claims invalid, the IPR proceeding is an independent action at the Patent Trial and Appeal Board (PTAB) that could also result in the invalidation of the patent claims. The outcome of the IPR could impact any potential appeal of the ITC's decision.

In Juul Labs Inc. v. Altria et al. (337-TA-1460), Juul Labs Inc. was represented by attorneys from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C..

Here are some of the counsel of record representing Juul Labs Inc.:

• Michael T. Renaud - Attorney

  • Firm: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C.
  • Note: Michael Renaud is a Member at Mintz, focusing on patent litigation and other intellectual property matters.

• Adam Rizk - Attorney

  • Firm: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C.

• Matthew Hurley - Attorney

  • Firm: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C.

Altria and its NJOY unit were represented by several law firms in Juul Labs Inc. v. Altria et al. (337-TA-1460), including Weil, Gotshal & Manges LLP and Fish & Richardson P.C..

Here is a breakdown of the counsel of record representing the defendant(s):

• Jonathan E. Singer - Lead Counsel

  • Firm: Fish & Richardson P.C. (San Diego, CA)
  • Note: Jonathan Singer is recognized for his extensive experience in intellectual property litigation, particularly in pharmaceutical patent disputes. He has successfully represented clients in significant cases at the Federal Circuit and even the U.S. Supreme Court, including reversing a $2.5 billion jury verdict against Gilead Sciences.

• Anne Y. Lee - Counsel

  • Firm: Covington & Burling LLP (Washington, D.C.)
  • Note: Anne Lee co-chairs Covington's global Antitrust and Competition Law Practice Group and advises clients on complex antitrust litigation, strategic transactions, and government investigations. While her primary focus appears to be antitrust, her firm's involvement suggests a role in the broader litigation strategy for Altria.

• Matthew J. Antonelli - Counsel

  • Firm: Antonelli, Harrington & Thompson LLP (Houston, TX)
  • Note: Matthew Antonelli has extensive experience litigating patent cases, including examining witnesses at trial, arguing substantive motions and Markman hearings, and conducting jury studies. He previously was counsel to Weil, Gotshal & Manges. His experience includes patent infringement actions across various technologies like semiconductors, consumer electronics, and chemistry.

Other attorneys from Fish & Richardson are also listed as representing the respondents. Weil, Gotshal & Manges LLP is also noted for its significant patent litigation experience, including representing Altria in other competitor patent infringement suits.